SCHEMBL4263153

SCHEMBL4263153

Cc1c(-c2csc(-c3cnccc3C(F)(F)F)n2)ccc2c1NC(=O)CO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 3/20 0.41
MAP4K1 Q92918 1/20 0.41
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 5/20 0.36
MAPT P10636 5/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 2/20 0.36
MAPK1 P28482 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
CDK5 Q00535 4/20 0.35
CDK5R1 Q15078 4/20 0.35
HPGD P15428 1/20 0.35
CYP19A1 P11511 1/20 0.33
LMNA P02545 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
PIM1 P11309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258381 0.89 NR3C2 (0.47) NR3C2MAP4K1POLBALDH1A1MAPT
SCHEMBL4258355 0.82 CYP17A1 (0.51) NR3C2POLBKDM4ETDP1ALDH1A1
SCHEMBL4264485 0.79 NR3C2 (0.49) NR3C2MAP4K1POLBTDP1ALDH1A1
SCHEMBL4267847 0.79 NR3C2 (0.48) NR3C2MAP4K1POLBKDM4EALDH1A1
SCHEMBL4258380 0.79 POLB (0.51) NR3C2MAP4K1POLBKDM4EALDH1A1
SCHEMBL4260398 0.78 NR3C2 (0.56) NR3C2MAP4K1POLBKDM4EALDH1A1
SCHEMBL4264898 0.77 POLB (0.47) NR3C2MAP4K1POLBKDM4EALDH1A1
SCHEMBL4265368 0.77 NR3C2 (0.48) NR3C2MAP4K1POLBKDM4EALDH1A1
SCHEMBL4267726 0.76 NR3C2 (0.46) NR3C2MAP4K1POLBALDH1A1MAPT
SCHEMBL4261043 0.75 POLB (0.49) NR3C2MAP4K1POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 NR3C2 7/4885MAP4K1 1567/4885POLB 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.